IRIDEX Corporation (IRIX)

NASDAQ: IRIX · IEX Real-Time Price · USD
2.18
+0.02 (0.74%)
At close: Jun 2, 2023, 3:54 PM
2.11
-0.07 (-3.03%)
After-hours: Jun 2, 2023, 7:16 PM EDT
0.74%
Market Cap 34.42M
Revenue (ttm) 57.29M
Net Income (ttm) -7.25M
Shares Out 16.01M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,297
Open 2.16
Previous Close 2.16
Day's Range 2.12 - 2.24
52-Week Range 1.96 - 3.49
Beta 1.26
Analysts Hold
Price Target 3.00 (+37.87%)
Earnings Date May 11, 2023

About IRIX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems tha... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 15, 1996
Employees 130
Stock Exchange NASDAQ
Ticker Symbol IRIX
Full Company Profile

Financial Performance

In 2022, IRIDEX's revenue was $56.97 million, an increase of 5.69% compared to the previous year's $53.90 million. Losses were -$7.55 million, 44.4% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for IRIX stock is "Hold" and the 12-month stock price forecast is $3.0.

Price Target
$3.0
(37.87% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Iridex to Report First Quarter Financial Results on May 11, 2023

MOUNTAIN VIEW, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 month ago - GlobeNewsWire

Iridex Reports Fourth Quarter and Full Year 2022 Financial Results

Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth

3 months ago - GlobeNewsWire

Iridex to Present at the 35th Annual Roth Conference

MOUNTAIN VIEW, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

3 months ago - GlobeNewsWire
}

Iridex Introduces New Research and Showcases Five Events at the AGS Meeting

Five Events at Booth #5

3 months ago - GlobeNewsWire

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

3 months ago - GlobeNewsWire

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022

Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth

5 months ago - GlobeNewsWire

Iridex to Participate in Fireside Chat with Stifel Equity Research

MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

6 months ago - GlobeNewsWire

Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022

MicroPulse® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways t...

8 months ago - GlobeNewsWire
}

Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

MOUNTAIN VIEW, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

10 months ago - GlobeNewsWire

Iridex Announces Second Quarter 2022 Financial Results

MOUNTAIN VIEW, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022.

10 months ago - GlobeNewsWire

Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022

MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

10 months ago - GlobeNewsWire

Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China

MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

1 year ago - GlobeNewsWire

Iridex Announces First Quarter 2022 Financial Results

Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue

1 year ago - GlobeNewsWire
}

Iridex to Report First Quarter 2022 Financial Results on May 12, 2022

MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

Iridex Announces the Appointment of Beverly Huss to its Board of Directors

MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

Iridex Announces Fourth Quarter and Full Year 2021 Financial Results

Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth

1 year ago - GlobeNewsWire

Iridex to Present at the 34th Annual Roth Conference

MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

Iridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

MOUNTAIN VIEW, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

1 year ago - GlobeNewsWire

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021

Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth

1 year ago - GlobeNewsWire

Iridex Announces Third Quarter 2021 Financial Results

Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance

1 year ago - GlobeNewsWire

Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting

An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021

1 year ago - GlobeNewsWire

Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021

MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal d...

1 year ago - GlobeNewsWire

Iridex to Present at the Lytham Partners Fall 2021 Investor Conference

MOUNTAIN VIEW, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

1 year ago - GlobeNewsWire

Iridex Stock Gains After Posting Highest Sales Since 2007

Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million. Cyclo G6 product family generated sales of $3.6 mill...

1 year ago - Benzinga

Iridex: Q2 Earnings Insights

Shares of Iridex (NASDAQ:IRIX) moved higher by 1.4% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 145.00% over the past year to $0.09, which ...

1 year ago - Benzinga